Spotlight
Clinical
CME
Partners
Studies explore anecortave acetate to treat, prevent CNV
Fort Lauderdale, FL-A series of studies is evaluating the angiostatic cortisene compound anecortave acetate (Retaane, Alcon Laboratories) as both a prophylactic and therapeutic intervention for choroidal neovascularization (CNV) in eyes with age-related macular degeneration (AMD), said Jason S. Slakter, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Related Videos
View All
Related Content
